HOC is our outreach and engagement site which connects us with healthcare professionals, industry personnel and academics worldwide.
Our HOC platform shares blogs from experienced medical writers around the world, bringing you tips on good communication, evaluations of current health economics and outcomes research and healthcare evidence. Mixed in with great information you will find a light-hearted approach to current issues, some valuable downloads, as well as references for further reading.
By Mary Gabb (mary.gabb@rxcomms.com) As health economics plays a more prominent role in medical research and public policy, participation in panel discussions – either in front of a live audience…
Details
While economics is the main ingredient in most healthcare decisions today, health economics still has many pharmacologists, clinicians, physicians and marketing personnel left confused and appalled that quality of life…
Details
By Robert Hand (robert.hand@rxcomms.com) For those interested in entering or advancing in the field of health economics and outcomes research, and for those looking for newly-minted researchers to employ, it…
Details
By David Woods (david.woods@rxcomms.com) Dr. Patti Peeples: what a perfect name for the subject of HOC people! She tells me that the origin of the name is from Peebles, in…
Details
By David Woods (david.woods@rxcomms.com) The Wall Street Journal published an editorial last month titled “The Lancet’s Political Hit.” It described how that venerable medical journal had published a study exaggerating…
Details
The pharmaceutical industry faces the major issue of top selling drugs losing their patent protection, allowing generic products to replace them at much lower prices.
Details
By Julie Stauffer (julie.stauffer@rxcomms.com) The media can be a powerful vehicle for raising your profile, getting your message out and gaining credibility, but not everyone feels comfortable confronting a reporter’s…
Details
Recent reports in the Wall Street Journal and The Economist describe an imminent seismic shift in business models for pharmaceutical companies, as current blockbuster drugs are set to go off-patent and a rapidly dwindling pipeline of new drugs are under development or are being reviewed for approval.
Details
By Mary Gabb (mary.gabb@rxcomms.com) A frequently overlooked professional skill – especially among scientists – is public speaking, yet the inability to effectively communicate your work can place significant roadblocks in…
Details
By David Woods (david.woods@rxcomms.com) A pair of economists, Charles Jones of the University of California at Berkeley and Robert Hall of Stanford University, predict that the share of income devoted…
Details
